DMKC Advisory Services LLC Raises Stock Position in Pfizer Inc. $PFE

DMKC Advisory Services LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 21.2% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 117,624 shares of the biopharmaceutical company’s stock after buying an additional 20,584 shares during the quarter. DMKC Advisory Services LLC’s holdings in Pfizer were worth $2,832,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of PFE. Brighton Jones LLC raised its holdings in shares of Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC increased its position in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares in the last quarter. United Bank raised its position in shares of Pfizer by 12.4% in the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after purchasing an additional 6,415 shares during the last quarter. Sei Investments Co. raised its stake in Pfizer by 31.5% in the 2nd quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock worth $63,889,000 after acquiring an additional 631,523 shares during the last quarter. Finally, HUB Investment Partners LLC raised its position in Pfizer by 45.3% during the 2nd quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock worth $2,480,000 after buying an additional 31,896 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have weighed in on PFE shares. Bank of America cut their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research note on Monday, July 6th. HSBC cut shares of Pfizer from a “buy” rating to a “hold” rating and lowered their price target for the company from $32.00 to $28.00 in a research report on Monday, July 6th. Wolfe Research reissued an “underperform” rating and set a $26.00 price objective on shares of Pfizer in a research report on Thursday, May 14th. Finally, UBS Group restated a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Wednesday, May 27th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $28.50.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q2 results exceeded expectations. Pfizer reported adjusted earnings of $0.77 per share versus the $0.68 analyst consensus and revenue of $15.03 billion versus $14.40 billion expected. Revenue rose 2.6% year over year, led in part by strong demand for the blood thinner Eliquis. Pfizer beats quarterly profit estimates on strong demand for blood thinner Eliquis
• Positive Sentiment: Pfizer raised its 2026 revenue outlook. The company increased its revenue range to $60.5 billion-$62.5 billion from $59.5 billion-$62.5 billion, lifting the midpoint by $500 million while reaffirming adjusted EPS guidance of $2.80-$3.00. Growth from oncology, launched products and acquired medicines is helping offset weaker COVID sales. Pfizer tops quarterly estimates and hikes revenue guidance
• Positive Sentiment: Additional savings could support profitability. Pfizer targeted $2.5 billion in further cost reductions, expected to be implemented by 2029, as it works to improve efficiency and reduce reliance on older products. Pfizer targets additional cost cuts
• Positive Sentiment: Pipeline news adds potential upside. Pfizer reported positive Phase 3 data for Litfulo in vitiligo, while investors are also watching an obesity-treatment candidate and expanded oncology research for future growth catalysts. Pfizer reports positive Phase 3 Litfulo data
• Neutral Sentiment: Healthcare deal speculation and Pfizer’s acquisition activity remain additional factors investors are monitoring, but no transaction was confirmed in the reported coverage.
• Negative Sentiment: COVID vaccine and treatment demand continues to decline, and Pfizer still faces patent expirations and questions about whether its pipeline can replace lost blockbuster revenue. The quarter also included a reported net loss, while EPS guidance remains slightly below the analyst consensus.

Pfizer Trading Up 1.4%

NYSE PFE opened at $25.76 on Thursday. The company’s fifty day simple moving average is $25.01 and its 200-day simple moving average is $26.16. The stock has a market cap of $146.84 billion, a P/E ratio of 33.90 and a beta of 0.34. Pfizer Inc. has a 52 week low of $23.58 and a 52 week high of $28.75. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. The company had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a return on equity of 19.38% and a net margin of 6.80%.Pfizer’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts predict that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. Pfizer’s payout ratio is 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.